FDA Approves Morphine Sulfate Injection for Severe Pain Requiring Opioid Analgesic
The FDA has approved Morphine Sulfate Injection, an opioid agonist, for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The approval underscores the importance of reserving this medication for patients who have not tolerated or achieved adequate analgesia with non-opioid alternatives or opioid combination products. Clinicians are advised to use the lowest effective dose for the shortest duration necessary, as many acute pain conditions require only a few days of opioid therapy. The drug is available in two concentrations for direct intravenous or intramuscular injection, and dosing must be individualized based on pain severity, prior treatment, and risk factors for addiction. Respiratory depression is a key risk, especially during initiation and dose adjustments.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Morphine is an opioid agonist that binds to mu-opioid receptors in the central nervous system, producing analgesia.
Morphine Sulfate Injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. It should be reserved for patients who have not tolerated or not achieved adequate analgesia with non-opioid analgesics or opioid combination products. It should not be used for an extended period unless pain remains severe and alternative options continue to be inadequate.
Morphine Sulfate Injection is for intravenous and intramuscular use. For direct IV injection, initiate with 0.1 mg to 0.2 mg per kg every 4 hours as needed. For IM injection, initiate with 10 mg every 4 hours as needed (based on a 70 kg adult). Use the lowest effective dose for the shortest duration. Avoid dosing errors between mg and mL and between different concentrations. Administer slowly; rapid IV may cause chest wall rigidity. Do not abruptly discontinue in physically dependent patients.
Trial data not available in label.
Risks include addiction, abuse, misuse, and respiratory depression, which can occur at any dosage or duration. Reserve for patients with inadequate alternatives. Many acute pain conditions require only a few days of opioid therapy. Respiratory depression is a key risk, especially during initiation and dose increases.
Morphine Sulfate Injection is an opioid agonist for severe pain when non-opioid alternatives are inadequate. It should be used at the lowest effective dose for the shortest duration, with careful monitoring for respiratory depression and addiction risk.
View Original Abstract ↓
Intravenous tenecteplase improves functional outcomes but increases hemorrhage risk in non-large vessel occlusion acute ischemic stroke
Tenecteplase improves stroke recovery but increases bleeding risk in late treatment window
Related in Neurology
From Other Specialties
